Varga Zsuzsanna, Tubbs Raymond R, Moch Holger
Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland.
Section of Molecular Pathology, Cleveland Clinic, Cleveland, Ohio, United States of America.
PLoS One. 2014 Aug 25;9(8):e105961. doi: 10.1371/journal.pone.0105961. eCollection 2014.
HER2 status assessment became a mandatory test assay in breast cancer, giving prognostic and predictive information including eligibility for adjuvant anti-HER2 therapy. Precise and reliable assessment of HER2 status is therefore of utmost importance. In this study we analyzed breast cancer samples by a novel technology for concomitant detection of the HER2 protein and gene copy number.
Tissue microarrays containing 589 invasive breast cancer samples were analyzed with a double immunohistochemistry (IHC) and silver labeled in situ hybridization (SISH) assay simultaneously detecting HER2 protein and gene copy number in the same tumor cells. This bright-field assay was analyzed using scores according to the modified ASCO guidelines and the results were correlated with patient prognosis.
Overall concordance rate between protein expression and the presence of gene amplification was 98%. Fifty-seven of 60 tumors (95%) with IHC score 3+, 6 of 10 tumors with IHC score 2+ (60%) and only 3 of 519 tumors (0.6%) with IHC score 0/1+ were amplified by SISH. Patients with gene amplification despite IHC score 0/1+ had a tendency for worse overall survival (p = 0.088, reaching nearly statistical significance) compared to IHC score 0/1+ without amplification. In contrast, there was no difference in overall survival in IHC score 3+/2+ tumors with and without gene amplification.
The novel double IHC and SISH assay for HER2 is efficient in the identification of breast cancer with discordant HER2 protein and HER2 gene status, especially for the prognostically relevant groups of HER2 protein negative tumors with HER2 amplification and HER2 protein positive tumors without HER2 amplification. Breast cancer without HER2 amplification among IHC score 2+/3+ tumors (10% in our cohort) suggests that other mechanisms than gene amplification contribute to protein overexpression in these cells.
人表皮生长因子受体2(HER2)状态评估已成为乳腺癌的一项强制性检测分析,可提供预后和预测信息,包括辅助抗HER2治疗的适用性。因此,精确可靠地评估HER2状态至关重要。在本研究中,我们采用一种新技术分析乳腺癌样本,以同时检测HER2蛋白和基因拷贝数。
使用双免疫组织化学(IHC)和银标记原位杂交(SISH)分析方法,对包含589例浸润性乳腺癌样本的组织微阵列进行分析,在同一肿瘤细胞中同时检测HER2蛋白和基因拷贝数。采用根据改良美国临床肿瘤学会(ASCO)指南的评分对这种明场分析进行评估,并将结果与患者预后相关联。
蛋白表达与基因扩增之间的总体一致性率为98%。免疫组化(IHC)评分为3+的60例肿瘤中有57例(95%)、IHC评分为2+的10例肿瘤中有6例(60%)以及IHC评分为0/1+的519例肿瘤中仅有3例(0.6%)通过SISH检测为扩增。与无扩增的IHC评分为0/1+的患者相比,尽管IHC评分为0/1+但基因扩增的患者总生存期有较差的趋势(p = 0.088,接近统计学意义)。相比之下,基因扩增和无基因扩增的IHC评分为3+/2+的肿瘤患者总生存期无差异。
用于HER2检测的新型双免疫组化和SISH分析方法,在识别HER2蛋白和HER2基因状态不一致的乳腺癌方面效率较高,特别是对于HER2蛋白阴性肿瘤伴HER2扩增以及HER2蛋白阳性肿瘤无HER2扩增这些与预后相关的组别。免疫组化评分为2+/3+的肿瘤中无HER2扩增的乳腺癌(在我们的队列中占10%)提示,除基因扩增外的其他机制导致了这些细胞中的蛋白过表达。